Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Abstract Background The use of DTG-containing two-drug regimens is one of the most promising solutions to the need to ease the management of HIV treatment without harming its efficacy and safety. We report long- term results in patients switched, while virologically suppressed, to the combination of...

Full description

Bibliographic Details
Main Authors: Franco Maggiolo, Roberto Gulminetti, Layla Pagnucco, Margherita Digaetano, Adriana Cervo, Daniela Valenti, Annapaola Callegaro, Cristina Mussini
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Infectious Diseases
Subjects:
Dual ART
Dolutegravir
Lamivudine
Switch
Simplification
Long-term follow-up
Online Access:https://doi.org/10.1186/s12879-022-07769-6

Internet

https://doi.org/10.1186/s12879-022-07769-6

Similar Items